Authors available to discuss clinical studies results regarding Nalbuphine ER for hemodialysis patients with uremic pruritus
New Haven, CT, April 28, 2016 – Trevi Therapeutics, Inc. (“Trevi”), a late-stage clinical development company developing Nalbuphine ER for chronic pruritus conditions, will present two posters at the National Kidney Foundation Spring 2016 Meeting in Boston, MA on April 28.
The two posters regarding Trevi’s uremic pruritus clinical trials are Nalbuphine ER Tablets in Hemodialysis Patients with Severe Uremic Pruritus: Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial, and Long-Term Effects of Nalbuphine ER Tablets in Hemodialysis Patients with Uremic Pruritus: A Multicenter Open-Label Trial.
Authors Vandana S. Mathur M.D., Paul W. Crawford, M.D., and Thomas Sciascia, M.D. will be available during the posters presentation from 6:00-7:30 PM.
“It is exciting to the see the growing interest in chronic pruritus at various medical meetings by both nephrologists and dermatologists,” said Thomas Sciascia, M.D. Trevi’s Chief Medical Officer. “This is the largest to date randomized trial in uremic pruritus and it demonstrated the efficacy of Nalbuphine ER for one of the most distressing complications of end stage renal disease, and in the most severe uremic pruritus population.”
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a late-stage clinical development company focused on developing Nalbuphine ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic and neuropathic conditions. The Company is pursuing two conditions for clinical development: uremic pruritus and prurigo nodularis. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with increased mortality. Prurigo nodularis is a chronic pruritic dermatologic condition characterized by the presence of nodules on the skin. There are no approved therapies in the U.S. or EU for either condition.
Nalbuphine ER is an oral extended release opioid with a dual mechanism of action, mu receptor antagonist and kappa receptor agonist, both of which have been shown in research to be effective in abolishing itch. Because of Nalbuphine ER’s unique dual mechanism of action, which has shown efficacy in addressing pruritus in both animal studies and human clinical trials, the Company believes it can have broad utility in treating chronic pruritus.
Founded in 2011, Trevi is headquartered in New Haven, CT.
For additional information, visit www.trevitherapeutics.com.